Lung Cancer in COPD Patients: Development and Validation of the COPD Lung Cancer Screening Score (COPD-LUCSS)
de-Torres JP [SP] (1), Wilson DO, Sanchez-Salcedo P, Weissfeld JL, Berto J [SP], Campo A [SP], Alcaide AB [SP], García-Granero M, Celli BR, Zulueta JJ.
(1) Clinica Universidad de Navarra, Pulmonary, Pamplona, Spain
Magazine: American Journal of Respiratory and Critical Care Medicine
Date: Dec 18, 2014Pneumology
Patients with chronic obstructive pulmonary disease (COPD) are at high-risk for lung cancer (LC) and represent a potential target to improve the diagnostic yield of screening programs.
Develop a predictive score for LC risk for patients with COPD.
The Pamplona-IELCAP LC screening study (P-IELCAP) and the Pittsburgh Lung Screening Study (PLuSS) databases were analyzed. Only patients with COPD on spirometry were included. By logistic regression we determined which factors were independently associated with LC in PLuSS and developed a COPD lung cancer screening score (COPD-LUCSS) to be validated in P-IELCAP.
By regression analysis, age>60, BMI<25 kg/m2, pack-years history>60, and emphysema presence were independently associated with LC diagnosis and integrated into the COPD-LUCSS that ranges from 0 to 10 points.
Two COPD-LUCSS risk categories were proposed: low risk (scores 0-6) and high risk (scores 7-10). In comparison to low risk patients, in both cohorts LC risk increased 3.5 fold in the high-risk category.
The COPD-LUCSS is a good predictor of lung cancer risk in COPD patients participating in LC screening programs. Validation in two different populations adds strengths to the findings.
CITATION Am J Respir Crit Care Med. 2014 Dec 18
you maybe interested
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.